Evaluating Intracranial Response with DXd ADCs & Other Biologics: Lessons Learned & Opportunities Ahead
- Traditionally, large molecules including ADCs are thought to have no intracranial efficacy due to inability to cross the blood brain barrier
- Presenting evidence of intracranial efficacy of multiple DXd ADCs and mAbs, challenging this dogma
- Explaining this information can be utilised to address the unmet needs for patients with brain metastases